U-Turn or Norm? #NoGoingBack and Decentralized Trials in a post-COVID-19 World
*** Tuesday, December 15, 2020, at 1pm EST| 12pm CST| 10am PST *** COVID-19 has had a profound impact on clinical trials, patient recruitment and retention efforts, and accelerated the digital transformation roadmaps at sponsors and CROs. As an industry, we learned bold new ways to conduct trails. Virtual visits and remote patient monitoring have provided new options for data collection, quickly becoming the norm in the current environment recommending social distancing. But will the industry continue to embrace these changes in a post-COVID-19 world? *** On demand available after final airing until Dec. 15, 2021 ***
Register free: https://www.appliedclinicaltrialsonline.com/act_w/nogoingback
Event Overview:
The effect of the pandemic on clinical trials has been profound. We have seen leaders in the pharmaceutical industry deciding with speed over precision, adapting boldly, reliably delivering and engaging for impact, to support the management of this crisis.
COVID-19 has resulted in the compression of often decades-long digital transformation roadmaps, as well as, the adoption of new innovation strategies, such as decentralized clinical trials, to respond to the realities of shelter-in-place directives.
Stakeholders have been very vocal – there is no turning back – cumulating in the #NoGoingBack movement, arguing that the pace of innovation adoption must continue in a post-COVID-19 world.
But what is the anticipated impact of decentralized clinical trials on sponsors, CROs, investigative sites, and patients? Is the industry as a whole ready to make a switch to a more patient centric approach to running clinical trials? Or more importantly, will the industry embrace this change or revert back to its old ways post-COVID-19?
Key Learning Objectives:
In this webcast we will explore:
- Impact of COVID-19 on the adoption of decentralized clinical trials
- Perceived benefits of decentralized clinical trials from a sponsor, CRO and site perspective
- Expectation of when decentralized clinical trials will be available at scale coupled with the es-timated costs relative to traditional studies
- Challenges to the implementation of decentralized clinical trials and misalignment amongst stakeholders
Speakers: Craig Lipset, Former Head of Innovation, Pfizer; Advisor and Founder, Clinical Innovation Partners
Casey Orvin, Senior VP of Pharmaceutical Relationships, Study KIK; Honorary President, SCRS
Joan Chambers, Senior Director, Marketing & Outreach Center for Information and Study on Clinical Research Participation (CISCRP)
Katherine Vandebelt, Vice President of Global Innovation, Oracle Health Sciences
Time and Date: Tuesday, December 15, 2020, at 1pm EST| 12pm CST| 10am PST
On demand available after final airing until Dec. 15, 2021
Register free: https://www.appliedclinicaltrialsonline.com/act_w/nogoingback
